European Commission adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo – Novartis
On 26 May 2023, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended revoking the conditional marketing authorization (MA) for crizanlizumab. On 3… read more.
